更正：肌肉减少症作为不可切除肝细胞癌经动脉单纯栓塞治疗患者生存的预测指标。
Correction: Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.
作者信息
Lanza Ezio, Masetti Chiara, Messana Gaia, Muglia Riccardo, Pugliese Nicola, Ceriani Roberto, de Nalda Ana Lleo, Rimassa Lorenza, Torzilli Guido, Poretti Dario, D'Antuono Felice, Politi Letterio Salvatore, Pedicini Vittorio, Aghemo Alessio
出版信息
PLoS One. 2020 Oct 28;15(10):e0241715. doi: 10.1371/journal.pone.0241715. eCollection 2020.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0232371.].
摘要
[本文更正了文章的数字对象标识符：10.1371/journal.pone.0232371。]
相似文献
1
Correction: Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.更正：肌肉减少症作为不可切除肝细胞癌经动脉单纯栓塞治疗患者生存的预测指标。
PLoS One. 2020 Oct 28;15(10):e0241715. doi: 10.1371/journal.pone.0241715. eCollection 2020.
2
Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.肌少症作为不可切除肝细胞癌患者行单纯经动脉栓塞治疗后生存的预测因子。
PLoS One. 2020 Jun 17;15(6):e0232371. doi: 10.1371/journal.pone.0232371. eCollection 2020.
3
Correction: Transarterial strategies for the treatment of unresectable hepatocellular carcinoma: A systematic review.更正：经动脉治疗不可切除肝细胞癌的策略：一项系统评价。
PLoS One. 2020 Mar 6;15(3):e0230369. doi: 10.1371/journal.pone.0230369. eCollection 2020.
4
Overall survival after transarterial lipiodol infusion chemotherapy with or without embolization for unresectable hepatocellular carcinoma: propensity score analysis.不可切除肝细胞癌经肝动脉碘油化疗栓塞与单纯化疗栓塞治疗后的总生存：倾向评分分析。
AJR Am J Roentgenol. 2010 Mar;194(3):830-7. doi: 10.2214/AJR.09.3308.
5
Interstitial Brachytherapy in Combination With Previous Transarterial Embolization in Patients With Unresectable Hepatocellular Carcinoma.不可切除肝细胞癌患者间质近距离放射治疗联合既往经动脉栓塞术
Anticancer Res. 2019 Mar;39(3):1329-1336. doi: 10.21873/anticanres.13245.
6
Correction: Complex interaction networks of cytokines after transarterial chemotherapy in patients with hepatocellular carcinoma.更正：肝细胞癌患者经动脉化疗后细胞因子的复杂相互作用网络
PLoS One. 2020 Feb 19;15(2):e0229552. doi: 10.1371/journal.pone.0229552. eCollection 2020.
7
Correction: Effectiveness of intraprocedural dual-phase cone-beam computed tomography in detecting hepatocellular carcinoma and improving treatment outcomes following conventional transarterial chemoembolization.更正：术中双期锥形束计算机断层扫描在检测肝细胞癌及改善常规经动脉化疗栓塞术后治疗效果方面的有效性。
PLoS One. 2021 Feb 19;16(2):e0247648. doi: 10.1371/journal.pone.0247648. eCollection 2021.
8
Corrigendum: The Significance of Transarterial Chemo(embolization) Combined With Tyrosine Kinase Inhibitors and Immune Check Point Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review.勘误：经动脉化疗（栓塞）联合酪氨酸激酶抑制剂和免疫检查点抑制剂在全身治疗时代对不可切除肝细胞癌的意义：一项系统评价。
Front Immunol. 2022 Jun 7;13:952446. doi: 10.3389/fimmu.2022.952446. eCollection 2022.
9
Transarterial chemoembolization, transarterial chemotherapy, and intra-arterial chemotherapy for hepatocellular carcinoma treatment.经动脉化疗栓塞术、经动脉化疗和经动脉化疗治疗肝细胞癌。
Semin Oncol. 2010 Apr;37(2):89-93. doi: 10.1053/j.seminoncol.2010.03.007.
10
Survival analysis of 230 patients with unresectable hepatocellular carcinoma treated with bland transarterial embolization.230 例不可切除肝细胞癌患者行单纯性经肝动脉化疗栓塞治疗的生存分析。
PLoS One. 2020 Jan 14;15(1):e0227711. doi: 10.1371/journal.pone.0227711. eCollection 2020.
本文引用的文献
1
Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.肌少症作为不可切除肝细胞癌患者行单纯经动脉栓塞治疗后生存的预测因子。
PLoS One. 2020 Jun 17;15(6):e0232371. doi: 10.1371/journal.pone.0232371. eCollection 2020.
Zotero 插件